Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.42 |
| ▸ | FABP7 | O15540 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8815101 | 0.95 | KMT2A (0.45) | KMT2ATLR2FABP5FABP7CA1 | |
| SCHEMBL17744918 | 0.95 | KMT2A (0.51) | KMT2ATLR2FABP5FABP7CA1 | |
| SCHEMBL4970478 | 0.89 | KMT2A (0.53) | KMT2ATLR2FABP5FABP7CA1 | |
| SCHEMBL5577296 | 0.87 | KMT2A (0.49) | KMT2ATLR2FABP5FABP7CA1 | |
| SCHEMBL8575036 | 0.87 | KMT2A (0.49) | KMT2ATLR2FABP5FABP7CA1 | |
| SCHEMBL524545 | 0.86 | KMT2A (0.48) | KMT2ATLR2FABP5FABP7CA1 | |
| Hydrochloric Acid SCHEMBL13858072 | 0.86 | KMT2A (0.48) | KMT2ATLR2FABP5FABP7CA1 | |
| SCHEMBL525558 | 0.86 | KMT2A (0.48) | KMT2ATLR2FABP5FABP7CA1 | |
| SCHEMBL3976225 | 0.86 | KMT2A (0.48) | KMT2ATLR2FABP5FABP7CA1 | |
| SCHEMBL524835 | 0.86 | KMT2A (0.48) | KMT2ATLR2FABP5FABP7CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230010193-A1 | CHEMICAL METHODS FOR PRODUCING TAGGED NUCLEOTIDES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-12 | — | — | US | disclosed |
| US-11396677-B2 | Chemical methods for producing tagged nucleotides | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-07-26 | — | — | US | disclosed |
| EP-3122759-B1 | CHEMICAL METHODS FOR PRODUCING TAGGED NUCLEOTIDES | UNIV COLUMBIA (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-106715453-B | Chemical process for producing tagged nucleotides | 哥伦比亚大学董事会 | 2021-04-30 | — | — | CN | disclosed |
| US-20190276887-A1 | CHEMICAL METHODS FOR PRODUCING TAGGED NUCLEOTIDES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190248887-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | CENTROSE, LLC | 2019-08-15 | — | — | US | disclosed |
| US-10240195-B2 | Chemical methods for producing tagged nucleotides | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-03-26 | — | — | US | disclosed |
| EP-2475391-B1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | CENTROSE LLC (US) | 2018-09-12 | — | — | EP | disclosed |
| CN-106715453-A | Chemical methods for producing tagged nucleotides | 哥伦比亚大学董事会 | 2017-05-24 | — | — | CN | disclosed |
| EP-3122759-A1 | CHEMICAL METHODS FOR PRODUCING TAGGED NUCLEOTIDES | The Trustees of Columbia University in the City of New York (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2475391-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | Centrose, LLC (US) | 2012-07-18 | — | — | EP | disclosed |
| EP-2338057-A1 | MASS MARKERS AND METHODS | Brax Limited (GB) | 2011-06-29 | — | — | EP | disclosed |
| US-20110143951-A1 | MASS MARKERS AND METHODS | BRAX LIMITED (GB) | 2011-06-16 | — | — | US | disclosed |
| US-20110064752-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | CENTROSE, LLC (US) | 2011-03-17 | — | — | US | disclosed |
| WO-2011031870-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | CENTROSE, LLC (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2009153577-A1 | MASS MARKERS AND METHODS | BRAX LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| EP-0647133-A4 | COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY. | AFFYMAX TECH NV (AN) | 1997-10-29 | — | — | EP | disclosed |
| US-5607691-A | IONTOPHORESIS | AFFYMAX TECHNOLOGIES N.V. (GB) | 1997-03-04 | — | — | US | disclosed |
| EP-0647133-A1 | COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY | AFFYMAX TECHNOLOGIES N.V. (AN) | 1995-04-12 | — | — | EP | disclosed |
| WO-1993025197-A1 | COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY | AFFYMAX TECHNOLOGIES N.V. (AN) | 1993-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064752-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | FCGR2A, ENGASE, FCER2 | KMT2A 2710/4885TLR2 686/4885FABP5 895/4885 |
| US-20110143951-A1 | MASS MARKERS AND METHODS | PTMS, DCLRE1A, DCLRE1B | KMT2A 2857/4885TLR2 4546/4885FABP5 327/4885 |
| US-20190248887-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | FCGR2A, ENGASE, FCER2 | KMT2A 2710/4885TLR2 686/4885FABP5 895/4885 |
| US-20230010193-A1 | CHEMICAL METHODS FOR PRODUCING TAGGED NUCLEOTIDES | NT5C3B, NCL, NUDT1 | KMT2A 1493/4885TLR2 4707/4885FABP5 2749/4885 |
| US-11396677-B2 | Chemical methods for producing tagged nucleotides | NT5C3B, NCL, NUDT1 | KMT2A 1493/4885TLR2 4707/4885FABP5 2749/4885 |
| US-20190276887-A1 | CHEMICAL METHODS FOR PRODUCING TAGGED NUCLEOTIDES | NT5C3B, NCL, NUDT1 | KMT2A 1493/4885TLR2 4707/4885FABP5 2749/4885 |
| US-10240195-B2 | Chemical methods for producing tagged nucleotides | NT5C3B, NCL, NUDT1 | KMT2A 1493/4885TLR2 4707/4885FABP5 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.